Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases

Area of Science:

• Oncology
• Pharmacology

Background:

• Bone metastases are common in advanced non-small cell lung cancer (NSCLC), affecting 30-40% of patients.
• Zoledronic acid has demonstrated preclinical anticancer effects against lung cancer.

Purpose of the Study:

• To investigate the association between the duration of zoledronic acid treatment and patient outcomes in NSCLC with bone metastases.
• To evaluate the impact of zoledronic acid treatment length on survival and the incidence of malignant pleural effusion.

Main Methods:

• Retrospective analysis of 311 NSCLC patients with bone metastases treated between 2008-2011.
• Patients were divided into two groups based on zoledronic acid treatment frequency: >6 cycles (Group A) and <6 cycles (Group B).
• All patients received standard chemotherapy and other treatments; zoledronic acid was administered at 4 mg intravenously every 21-28 days.

Main Results:

• Survival time was significantly longer in Group A (385 days) compared to Group B (275 days) (P = 0.002).
• The incidence of malignant pleural effusion was significantly lower in Group A (22.0%) than in Group B (33.8%) (P = 0.041).

Conclusions:

• Extended zoledronic acid treatment duration (>6 cycles) is associated with improved survival in NSCLC patients with bone metastases.
• Longer zoledronic acid therapy may reduce the risk of malignant pleural effusion in this patient population.